2017
DOI: 10.1590/abd1806-4841.20175457
|View full text |Cite
|
Sign up to set email alerts
|

Primary cutaneous follicle center lymphoma

Abstract: Cutaneous lymphomas are classified according to their cellular origin into T-cell lymphoma and B-cell lymphoma. The annual incidence rate is 0.3 per 100,000 population. We report a case of a 56-year-old male patient who presented with a two-month history of nodules of varying sizes, some ulcerated, on the face, abdomen, and upper limbs. Histopathological examination and immunohistochemical study confirmed the diagnosis of primary cutaneous centrofollicular lymphoma. Studies have shown an increased incidence of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 6 publications
(8 reference statements)
0
5
0
Order By: Relevance
“…In addition, histopathological findings using both HE and IHC staining suggest the diagnosis of PCFCL with the findings of lymphocyte infiltrates on the dermis and subcutaneous forming a follicular/diffuse appearance, while there were no abnormalities found on the epidermis. There are various antibodies that can be used in IHC staining to confirm the diagnosis of PCFCL, such as CD20, PAX5, CD10, BCL2, and BCL6, in which, our case showed positive result for CD-20 antibody [9]. PCFCL is considered as a slow growing subtype of CBCL, with a 95% 5-year survival rate [3], [9], [10].…”
Section: Discussionmentioning
confidence: 94%
See 1 more Smart Citation
“…In addition, histopathological findings using both HE and IHC staining suggest the diagnosis of PCFCL with the findings of lymphocyte infiltrates on the dermis and subcutaneous forming a follicular/diffuse appearance, while there were no abnormalities found on the epidermis. There are various antibodies that can be used in IHC staining to confirm the diagnosis of PCFCL, such as CD20, PAX5, CD10, BCL2, and BCL6, in which, our case showed positive result for CD-20 antibody [9]. PCFCL is considered as a slow growing subtype of CBCL, with a 95% 5-year survival rate [3], [9], [10].…”
Section: Discussionmentioning
confidence: 94%
“…There are various antibodies that can be used in IHC staining to confirm the diagnosis of PCFCL, such as CD20, PAX5, CD10, BCL2, and BCL6, in which, our case showed positive result for CD-20 antibody [9]. PCFCL is considered as a slow growing subtype of CBCL, with a 95% 5-year survival rate [3], [9], [10].…”
Section: Discussionmentioning
confidence: 94%
“…The distinguishing histologic feature is a dense proliferation of neoplastic infiltrates in the dermis, which is separated from the epidermis by the grenz zone. 6 The clinical presentation of cutaneous metastatic carcinomas varies greatly, with 1 or multiple localized or widespread lesions commonly involving the abdominal wall, scalp, and face. The lesions also may mimic benign dermatologic conditions, thus potentially resulting in erroneous clinical diagnosis and delayed therapy of the primary malignancy.…”
Section: The Diagnosismentioning
confidence: 99%
“…PCFCL is the most common primary cutaneous B-cell lymphoma, representing about 55% of cases[ 1 2 ] and originating from B cells in the germinal centers of lymphoid follicles. It has a predilection for adult males with an average age of 60 years.…”
Section: Diagnosismentioning
confidence: 99%
“…Systemic and intralesional interferon-α alone or in combination with other treatments can also be used. [ 1 2 ]…”
Section: Diagnosismentioning
confidence: 99%